Replies to post #309 on Equity Field Notes from temporal sources

[DanWebzster]

IOVA focuses on TIL therapy in Metastatic Melanoma and has a relatively long cash runway.

IOVA is presently enrolling a Ph2 trial in Metastatic Melanoma

If the bloom continues to fade on CART-T therapies, the equity market may pay more attention to TIL

At present the burn rate, IOVA's cash runway extends into 2022.